News Column

Protea Enters Into Collaborative Research Agreement With the Memorial Sloan-Kettering Cancer Center and the Dana-Farber Cancer Institute

April 30, 2014



MORGANTOWN, W.Va., April 30, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) ("Protea") announced today it has begun a collaborative research initiative with the Memorial Sloan-Kettering Cancer Center (MSK) and the Dana-Farber Cancer Institute (Dana-Farber) that uses Protea's next generation LAESI direct molecular imaging technology to analyze cancer cells. The initial focus is early stage lung adenocarcinoma.

The studies will utilize LAESI technology to generate molecular data profiles of cancer cells in tissue and biofluids to improve the understanding of a cancer's origin. Protea's proprietary LAESI technology generates very large molecular data profiles of cancer cells in their native state, without the need for time-consuming sample preparation.

The principal investigators are Robert J. Downey, M.D. and Andre Moreira, M.D. at MSK and Franziska Michor, Ph.D. at Dana-Farber.

"We are pleased to have this opportunity to apply our LAESI technology to provide improved molecular profiling of cancer cells and tissue samples," commented Steve Turner, Protea's CEO. He added, "In the future we anticipate applying our direct molecular profiling technology to other tissue sample types, including 3 dimensional cell cultures and synthetic biology tissues, to provide comprehensive molecular profiling of tumors rapidly and directly."

About Protea Biosciences Group, Inc.

Protea is a commercial stage molecular information company, focused on meeting the needs of the pharmaceutical, biotechnology, agriculture, chemical and other industries with innovative technologies, software and services. Protea's proprietary technology, LAESI (Laser Ablation Electrospray Ionization), is used with mass spectrometry to detect the presence of up to, and over, one thousand distinct molecules from a single analysis of samples that can include tissues, cells, fluids, agricultural specimens and other sample types. Using proprietary software (ProteaPlotTM), the location of each distinct molecule in a respective sample can be displayed, enabling direct molecular imaging. The LAESI DP-1000, an integrated system that combines LAESI and ProteaPlot, is marketed to a wide array of researchers for numerous applications. Protea maintains its own laboratory facility where it performs services using LAESI and complementary technologies for a wide array of customers to support preclinical pharmaceutical R&D, biomarker discovery and other applications. Protea also collaborates with researchers to apply its technologies and expertise to generate new discoveries and intellectual property.

https://proteabio.com/investors

More Information on MSK:http://www.mskcc.org/

More Information on Dana-Farber:http://www.dana-farber.org/

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Additional information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.

CONTACT: Protea Biosciences Group, Inc.955 Hartman Run Road, Morgantown, WV 26505 USA Phone: 304.292.2226 Fax: 304.292.7101 steve.oloughlin@proteabio.com



Protea Biosciences, Inc. Logo

Source: Protea Biosciences, Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: GlobeNewswire - Canada


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters